The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: An update using the Sheffield Type 1 Diabetes Policy Model

Diabetic Medicine

Volumn 30, Issue 10, 2013, Pages 1236-1244

  Kruger, J ^a   Brennan, A ^a   Thokala, P ^a   Basarir, H ^a   Jacques, R ^a   Elliott, J ^b   Heller, S ^b   Speight, J ^c,d,e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c AHP Research   (United Kingdom)

^d THE AUSTRALIAN CENTRE FOR BEHAVIOURAL RESEARCH IN DIABETES   (Australia)

^e DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAFNE STRUCTURED EDUCATION PROGRAM; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFE EXPECTANCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SENSITIVITY ANALYSIS; SHEFFIELD TYPE 1 DIABETES POLICY MODEL; SIMULATION;

ADULT; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MODELS, ECONOMIC; PATIENT EDUCATION AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; SELF CARE; STATE MEDICINE;

EID: 84884716025     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12270     Document Type: Article

References (29)

1. Muhlhauser I, Jorgens V, Berger M, Graninger W, Gurtler W, Hornke L et al. Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia 1983; 25: 470-476.
2. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 2002; 325: 746.
3. National Collaborating Centre for Women's and Children's Health and the National Collaborating Centre for Chronic Conditions. Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children, Young People and Adults. Clinical guideline 15. Manchester, UK: National Collaborating Centre for Women's and Children's Health and the National Collaborating Centre for Chronic Conditions, 2004.
4. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. Third edition. Oxford: Oxford University Press, 2005.
5. NICE. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence, 2008.
6. Shearer A, Bagust A, Sanderson D, Heller S, Roberts S. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK. Diabet Med 2004; 21: 460-467.
7. Speight J, Amiel S, Bradley C, Heller S, Oliver L, Roberts S et al. Long-term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin therapy in adults with suboptimally controlled Type 1 diabetes. Diabetes Res Clin Pract 2010; 89: 22-29.
8. Speight J. Predicting outcomes in the Dose Adjustment for Normal Eating (DAFNE) Trial. Proceedings of the British Psychological Society-Division of Health Psychology Annual Conference, Queen Margaret University College, Edinburgh (8-10 September 2004), 2005: 89. Available at www.bps.org.uk/sites/default/files/images/ceproceedings13_1feb2005.pdf
9. Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A et al. The Sheffield Type 1 Diabetes Policy Model. 2013. Available at http://www.shef.ac.uk/scharr/sections/heds/discussion-papers Last accessed 2 May 2013.
10. Mansell P, Chater T, Cooke D, Emery C, Hopkins D, Lawrence I et al. A74: a research database for structured diabetes education (DAFNE). Diabet Med 2011; 28: S27.
11. Office for National Statistics. Interim Life Tables, UK, 1980-1982 to 2008-2010. Newport: Office for National Statistics, 2011. Available at http://www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2008-2010/sum-ilt-2008-10.html Last accessed 2 May 2013.
12. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjornsdottir S, on behalf on the Swedish National Diabetes Register. A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med 2011; 28: 1213-1220.
13. Eastman RC, Javitt JC, Herman WH, Dasbach E, Copley-Merriman C, Maier W et al. Model of complications of NIDDM II: analysis of the health benefits and cost-effectiveness of treatment NIDDM with the goal of normoglycaemia. Diabetes Care 1997; 20: 735-744.
14. Eastman RC, Javitt JC, Herman WH, Dasbach E, Zbrozek AS, Dong FB et al. Model of complications of NIDDM I: model construction and assumptions. Diabetes Care 1997; 20: 725-734.
15. Klein R, Knudtson M, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. The 25-year progression of retinopathy in persons with Type 1 diabetes. Ophthalmology 2008; 115: 1859-1868.
16. Klein R, Knudtson M, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII. The 25-year incidence of macular edema in persons with Type 1 diabetes. Ophthalmology 2009; 116: 497-503.
17. Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year incidence of visual impairment in Type 1 diabetes mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2010; 117: 63.
18. Palmer JL. Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Cardiovascular and End-Stage Renal Disease in Patients with Type 1 Diabetes. MSc Thesis. University of Sheffield, Sheffield, 2012.
19. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-1720.
20. The Diabetes Control and Complications Trial Research Group. Intensive treatment and cardiovascular disease in patients with Type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
21. Wolfe RA, Ashby VB, Milford E, Ojo A, Ettenger R, Agodoa L et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 2008; 341: 1725-1730.
22. Wong T, Shankar A, Klein R, Klein BE. Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with Type 1 diabetes. Diabetes 2004; 53: 179-184.
23. DAFNE. PU07.006, version 7-June 2012. Fact sheet 6. 2012. Available at www.DAFNE.uk.com Last accessed 2 May 2013.
24. van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.
25. Law A. Simulation Modelling and Analysis. Fourth edition. New York: McGraw-Hill, 2007.
26. Gunn D, Mansell P. Glycaemic control and weight 7 years after Dose Adjustment for Normal Eating (DAFNE) structured education in Type 1 diabetes. Diabet Med 2012; 29: 807-812.
27. Cooke D, Bond R, Lawton J, Rankin D, Heller S, Clark M et al. Structured Type 1 diabetes education delivered within routine care: impact on glycemic control and diabetes-specific quality of life. Diabetes Care 2013; 36: 270-272.
28. Hopkins D, Lawrence I, Mansell P, Thompson G, Amiel S, Campbell M et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with Type 1 diabetes: the UK DAFNE experience. Diabetes Care 2012; 35: 1638-1642.
29. Keen A, Duncan E, McKillop-Smith A, Evans N, Gold A. Dose Adjustment for Normal Eating (DAFNE) in routine clinical practice: who benefits? Diabet Med 2012; 29: 670-676.